Hunan Dajiaweikang Pharmaceutical IndustryLtd Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Shengli Hu

Algemeen directeur

CN¥637.9k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.2yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump

Oct 08

Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking

May 09

Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost

Mar 08

CEO

Shengli Hu (50 yo)

4.2yrs

Tenure

CN¥637,900

Compensatie

Ms. Shengli Hu is GM, Financial Director & Director of Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd from July 28, 2022. She was Financial Director, Board Secretary & Director of Hunan Dajiaweikang Ph...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Shengli Hu	GM, Financial Director & Director	7.2yrs	CN¥637.90k	geen gegevens
Shanhu Chen	Director & Deputy GM	1.1yrs	CN¥386.60k	0.097% CN¥ 2.2m
Yiqing Wang	Chairman of the Board	4.4yrs	CN¥685.80k	34.15% CN¥ 786.3m
Xuesong Zhong	Director	10.4yrs	CN¥240.00k	9.39% CN¥ 216.2m
Juan Tang	Chairman of the Supervisory Board	7.2yrs	geen gegevens	0.094% CN¥ 2.2m
Zhi Tang	Independent Director	5yrs	CN¥160.00k	geen gegevens
Shuping Liu	Independent Director	4.2yrs	CN¥160.00k	geen gegevens
Yu Deng	Supervisor	7.2yrs	geen gegevens	geen gegevens
Jia Peng	Employee Representative Supervisor	10.4yrs	geen gegevens	geen gegevens
Hao Chen	Independent Director	1.1yrs	CN¥42.60k	geen gegevens

6.1yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 301126 wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Hunan Dajiaweikang Pharmaceutical IndustryLtd Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd, Annual General Meeting, May 14, 2024

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.025 (vs CN¥0.029 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

There's Reason For Concern Over Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd's (SZSE:301126) Massive 41% Price Jump

New minor risk - Share price stability

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 27%

Second quarter 2024 earnings released: EPS: CN¥0.059 (vs CN¥0.016 in 2Q 2023)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd to Report First Half, 2024 Results on Aug 30, 2024

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) commences an Equity Buyback for CNY 15 million worth of its shares, under the authorization approved on April 15, 2024.

Less than half of directors are independent

Optimistic Investors Push Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Shares Up 30% But Growth Is Lacking

Investor sentiment improves as stock rises 29%

First quarter 2024 earnings released: EPS: CN¥0.09 (vs CN¥0.07 in 1Q 2023)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd, Annual General Meeting, May 14, 2024

Investor sentiment deteriorates as stock falls 20%

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Market Might Still Lack Some Conviction On Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) Even After 31% Share Price Boost

Investor sentiment deteriorates as stock falls 31%

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings released: EPS: CN¥0.029 (vs CN¥0.071 in 3Q 2022)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Approves Board Elections

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.016 (vs CN¥0.10 in 2Q 2022)

Investor sentiment deteriorates as stock falls 17%

Upcoming dividend of CN¥0.029 per share at 0.2% yield

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Implements Final Cash Dividend of A Shares for the Year 2022, Payable on June 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.09 in 1Q 2022)

Hunan Dajiaweikang Pharma to Buy 85.7% Stake in Pharma Firm

Third quarter 2022 earnings released: EPS: CN¥0.071 (vs CN¥0.097 in 3Q 2021)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd (SZSE:301126) completed the acquisition of 51% stake in Ningxia Delixin Medicine Co., Ltd. from Duan Junzhang, Duan Xisheng and Zhao Xupeng.

Second quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.10 in 2Q 2021)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 21 June 2022

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. Approves Cash Dividend

Full year 2021 earnings released: EPS: CN¥0.44 (vs CN¥0.42 in FY 2020)

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. Proposes Dividend for 2021

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Hunan Dajiaweikang Pharmaceutical Industry Co.,Ltd. has completed an IPO in the amount of CNY 638.618877 million.

CEO

Tenure

Compensatie

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd